Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases
Award Notice Posted
- Solicitation number
- HHS-NIH-NIAID-BAA2021-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Revagenix Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93022C00061 Federal contract award
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases awarded Revagenix, Inc. a cost-reimbursement contract valued at $26,427,820 for the development of medical countermeasures against biothreat agents, antimicrobial-resistant infections and emerging infectious diseases. This type of contract was selected as costs could not be adequately defined at the time of award. The contract was awarded on September 22, 2022 under a full and open competition by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases.
Notice text
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award.
Awarded contract 75N93022C00061 to Revagenix, Inc. for 26427820.00 on 2022-09-22.
Notice history
6 of 9 notices listed here. See the rest on GovTribe.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside | |
| Pre-Clinical Models of Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity